Baseline characteristics of patients
| Characteristics . | Phenotype of platelet donor . | ||
|---|---|---|---|
| Unselected (n = 28)* . | High responder (n = 49)† . | Low responder (n = 51)‡ . | |
| Age, mean (SD), y | 52.5 (16.0) | 52.2 (16.6) | 49.7 (17.8) |
| Male, no. (%) | 22 (79) | 29 (59) | 27 (53) |
| BSA, mean (SD) | 1.95 (0.20) | 1.91 (0.21) | 1.89 (0.24) |
| Diagnosis, no. (%) | |||
| Acute myeloid leukemia | 10 (36) | 15 (31) | 18 (35) |
| Acute lymphoblastic leukemia | 2 (7) | 3 (6) | 6 (12) |
| Chronic myeloid leukemia | 0 | 0 | 0 |
| Lymphoma | 7 (25) | 14 (29) | 15 (29) |
| Myeloma | 5 (18) | 9 (18) | 6 (12) |
| Other | 4 (14) | 8 (16) | 6 (12) |
| Treatment plan, no. (%) | |||
| Induction | 6 (21) | 8 (16) | 9 (18) |
| Consolidation | 1 (4) | 2 (4) | 4 (8) |
| Autograft | 10 (36) | 16 (33) | 10 (20) |
| Allograft | 6 (21) | 8 (16) | 12 (24) |
| Other | 5 (18) | 15 (31) | 16 (31) |
| Pretransfusion platelet count, mean (SD), ×109/L | 8.96 (3.81) | 9.73 (4.81) | 10.51 (5.94) |
| Irradiated platelets given, no. (%) | 27 (96) | 48 (98) | 50 (98) |
| Volume of platelets transfused, mean (SD), mL | 176 (13.6) | 175 (10.11) | 174 (12.42) |
| Platelet dose transfused, mean (SD), ×109 | 269 (49) | 264 (40) | 244 (30) |
| Platelet dose transfused per BSA, mean (SD), ×109/m2 | 140 (32) | 142 (27) | 130 (19) |
| Age of platelets, median (IQR), d | 4 (4-5) | 4 (3-5) | 4 (3-5) |
| ABO fully matched, no. (%) | 26 (93) | 47 (96) | 49 (96) |
| No. of donors§ | N/A | 15 | 16 |
| Characteristics . | Phenotype of platelet donor . | ||
|---|---|---|---|
| Unselected (n = 28)* . | High responder (n = 49)† . | Low responder (n = 51)‡ . | |
| Age, mean (SD), y | 52.5 (16.0) | 52.2 (16.6) | 49.7 (17.8) |
| Male, no. (%) | 22 (79) | 29 (59) | 27 (53) |
| BSA, mean (SD) | 1.95 (0.20) | 1.91 (0.21) | 1.89 (0.24) |
| Diagnosis, no. (%) | |||
| Acute myeloid leukemia | 10 (36) | 15 (31) | 18 (35) |
| Acute lymphoblastic leukemia | 2 (7) | 3 (6) | 6 (12) |
| Chronic myeloid leukemia | 0 | 0 | 0 |
| Lymphoma | 7 (25) | 14 (29) | 15 (29) |
| Myeloma | 5 (18) | 9 (18) | 6 (12) |
| Other | 4 (14) | 8 (16) | 6 (12) |
| Treatment plan, no. (%) | |||
| Induction | 6 (21) | 8 (16) | 9 (18) |
| Consolidation | 1 (4) | 2 (4) | 4 (8) |
| Autograft | 10 (36) | 16 (33) | 10 (20) |
| Allograft | 6 (21) | 8 (16) | 12 (24) |
| Other | 5 (18) | 15 (31) | 16 (31) |
| Pretransfusion platelet count, mean (SD), ×109/L | 8.96 (3.81) | 9.73 (4.81) | 10.51 (5.94) |
| Irradiated platelets given, no. (%) | 27 (96) | 48 (98) | 50 (98) |
| Volume of platelets transfused, mean (SD), mL | 176 (13.6) | 175 (10.11) | 174 (12.42) |
| Platelet dose transfused, mean (SD), ×109 | 269 (49) | 264 (40) | 244 (30) |
| Platelet dose transfused per BSA, mean (SD), ×109/m2 | 140 (32) | 142 (27) | 130 (19) |
| Age of platelets, median (IQR), d | 4 (4-5) | 4 (3-5) | 4 (3-5) |
| ABO fully matched, no. (%) | 26 (93) | 47 (96) | 49 (96) |
| No. of donors§ | N/A | 15 | 16 |
Values are means with standard deviation (SD) except for age of platelets (median with interquartile range [IQR]).
N/A, not available.
For dose transfused (×109 or 109 per BSA), n = 15.
For dose transfused (×109 or 109 per BSA), n = 44.
For pretransfusion platelet count, n = 49; and for dose transfused (×109 or 109 per BSA), n = 48.
The number of donors who have donated platelets transfused to patients. There were no significant differences between groups.